Nonhuman primate models for unit 12.14 HIV/AIDS vaccine development

Current Protocols in Immunology

Volumn , Issue SUPPL.102, 2013, Pages

  Sui, Yongjun ^a   Gordon, Shari ^a   Franchini, Genoveffa ^a   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Animal models; Macaques; Nonhuman primates; SIV; T cell immunity; Vaccines

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; POXVIRUS VECTOR; TRIPARTITE MOTIF PROTEIN 5; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ALLELE; ANIMAL GENETICS; APOBEC3G GENE; ARTICLE; DRUG EFFICACY; DRUG ISOLATION; DRUG SYNTHESIS; GENE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; MACACA; MAJOR HISTOCOMPATIBILITY COMPLEX; MAMU A 01 GENE; MAMU B 08 GENE; MAMU B 17 GENE; MHC GENE; MUCOSAL IMMUNITY; NONHUMAN; PRIMATE MODEL; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINATION; VACCINE PRODUCTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

EID: 84896342839     PISSN: 19343671     EISSN: 1934368X     Source Type: Journal    
DOI: 10.1002/0471142735.im1214s102     Document Type: Article

References (239)

1. Abimiku, A.G., Franchini,G., Tartaglia, J., Aldrich, K., Myagkikh, M., Markham, P.D., Chong, P., Klein, M.,Kieny,M.-P., Paoletti, E., Gallo,R.C., and Robert-Guroff, M. 1995. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat. Med. 1:321-329.
2. Agy, M.B., Frumkin, L.R., Corey, L., Coombs, R.W., Wolinsky, S.M., Koehler, J., Morton, W.R., and Katze, M.G. 1992. Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science 257:103-106.
3. Agy, M.B., Schmidt, A., Florey, M.J., Kennedy, B.J., Schaefer, G., Katze, M.G., Corey, L., Morton, W.R., and Bosch, M.L. 1997. Serial in vivo passage of HIV-1 infection in Macaca nemestrina. Virology 238:336-343.
4. Akari, H., Mori, K., Terao, K., Otani, I., Fukasawa, M., Mukai, R., and Yoshikawa, Y. 1996. In vitro immortalization of OldWorld monkey T lymphocytes with Herpesvirus saimiri: Its susceptibility to infection with simian immunodeficiency viruses. Virology 218:382-388.
5. Amara, R.R.,Villinger, F.,Altman, J.D., Lydy, S.L., O'Neil, S.P., Staprans, S.I., Montefiori, D.C., Xu, Y., Herndon, J.G., Wyatt, L.S., Candido, M.A., Kozyr, N.L., Earl, P.L., Smith, J.M., Ma, H.-L., Grimm, B.D., Hulsey, M.L., Miller, J., McClure, H.M.,McNicholl, J.M.,Moss, B., and Robinson, H.L. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.
6. Amara, R.R., Smith, J.M., Staprans, S.I., Montefiori, D.C., Villinger, F., Altman, J.D., O'Neil, S.P., Kozyr, N.L., Xu, Y., Wyatt, L.S., Earl, P.L., Herndon, J.G., McNicholl, J.M., McClure, H.M.,Moss, B., and Robinson, H.L. 2002. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76:6138-6146.
7. Anderson, D.J. 2010. Finally, a macaque model for cell-associated SIV/HIV vaginal transmission. J. Infect. Dis. 202:333-336.
8. Andersson, S., Mäkitalo, B., Thorstensson, R., Franchini, G., Tartaglia, J., Limbach, K., Paoletti, E., Putkonen, P., and Biberfeld, G. 1996. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J. Infect. Dis. 174:977-985.
9. Andris, J.S., Miller,A.B., Abraham, S.R., Cunningham, S., Roubinet, F., Blancher, A., and Capra, J.D. 1997. Variable region gene segment utilization in rhesus monkey hybridomas producing human red blood cell-specific antibodies: Predominance of the VH4 family but not VH4-21 (V4-34). Mol. Immunol. 34:237-253.
10. Baeten, J.M., Kahle, E., Lingappa, J.R., Coombs, R.W., Delany-Moretlwe, S., Nakku-Joloba, E., Mugo, N.R., Wald, A., Corey, L., Donnell, D., Campbell, M.S., Mullins, J.I., and Celum, C. 2011. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci. Trans. Med. 3:77ra29.
11. Baroncelli, S., Negri, D.R.M., Michelini, Z., and Cara,A. 2008. Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development. Exp. Rev. Vaccines 7:1419-1434.
12. Barouch, D.H., Liu, J., Li, H., Maxfield, L.F., Abbink, P., Lynch, D.M., Iampietro, M.J., SanMiguel, A., Seaman, M.S., Ferrari, G., Forthal, D.N., Ourmanov, I., Hirsch, V.M., Carville, A., Mansfield, K.G., Stablein, D., Pau, M.G., Schuitemaker, H., Sadoff, J.C., Billings, E.A., Rao, M., Robb, M.L., Kim, J.H., Marovich, M.A., Goudsmit, J., and Michael, N.L. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89-93.
13. Barré-Sinoussi, F., Chermann, J.C., Rey, F., Nugeyre, M.T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vézinet-Brun, F., Rouzioux, C., Rozenbaum,W., and Montagnier, L. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868-871.
14. Belyakov, I.M., Kuznetsov, V.A., Kelsall, B., Klinman, D., Moniuszko, M., Lemon, M., Markham, P.D., Pal, P., Clements, J.D., Lewis, M.G., Strober, S., Franchini, G., and Berzofsky, J.A. 2006. Impact of vaccine-induced mucosal high-avidity CD8+CTLs in delay ofAIDS viral dissemination from mucosa. Blood 107:3258-3264.
15. mac251: Dependence on route of challenge exposure. J. Virol. 72:4170-4182.
16. Bertley, F.M.N., Kozlowski, P.A., Wang, S.-W., Chappelle, J., Patel, J., Sonuyi, O., Mazzara, G., Montefiori, D., Carville, A., Mansfield, K.G., and Aldovini, A. 2004. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J. Immunol. 172:3745-3757.
17. Bible, J.M., Howard, W., Robbins, H., and Dunn-Walters, D.K. 2003. IGHV1, IGHV5 and IGHV7 subgroup genes in the Rhesus macaque. Immunogenetics 54:867-873.
18. Bomsel,M. 1997. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3:42-47.
19. Borsetti, A., Baroncelli, S., Maggiorella, M.T., Bellino, S., Moretti, S., Sernicola, L., Belli, R., Ridolfi, B., Farcomeni, S., Negri, D.R.M., Cafaro, A., Ensoli, B., and Titti, F. 2008. Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Arch. Virol. 153:463-472.
20. Boyer, J.D., Ugen, K.E., Wang, B., Agadjanyan, M., Gilbert, L., Bagarazzi, M.L., Chattergoon, M., Frost, P., Javadian, A., Williams, W.V., Refaeli, Y., Ciccarelli, R.B., McCallus, D., Coney, L., and Weiner, D.B. 1997. Protection of chimpanzees from high-dose heterologous HIV-1 challenge byDNAvaccination. Nat. Med. 3:526-532.
21. Boyson, J.E., Shufflebotham, C., Cadavid, L.F., Urvater, J.A., Knapp, L.A., Hughes, A.L., and Watkins, D.I. 1996. The MHC class I genes of the rhesus monkey. The MHC class I genes of the rhesus monkey. Different evolutionary histories of MHC class I and II genes in primates. J. Immunol. 156:4656-4665.
22. Brennan, G., Kozyrev, Y., Kodama, T., and Hu, S.-L. 2007.NovelTRIM5 isoforms expressed by Macaca nemestrina. J. Virol. 81:12210-12217.
23. Brennan, G., Kozyrev, Y., and Hu, S.-L. 2008. TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc. Natl. Acad. Sci. U.S.A. 105: 3569-3574.
24. Buchbinder, S.P., Mehrotra, D.V., Duerr, A., Fitzgerald, D.W., Mogg, R., Li, D., Gilbert, P.B., Lama, J.R., Marmor, M., del Rio, C., McElrath, M.J., Casimiro, D.R., Gottesdiener, K.M., Chodakewitz, J.A., Corey, L., and Robertson, M.N. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
25. Burdo, T.H.,Marcondes, M.C.G., Lanigan, C.M.S., Penedo, M.C.T., and Fox, H.S. 2005. Susceptibility of Chinese rhesus monkeys to SIV infection. AIDS 19:1704-1706.
26. Casimiro, D.R., Bett, A.J., Fu, T.-m., Davies, M.-E., Tang, A., Wilson, K.A., Chen, M., Long, R.,McKelvey, T., Chastain, M., Gurunathan, S., Tartaglia, J., Emini, E.A., and Shiver, J. 2004. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J. Virol. 78:11434-11438.
27. Casimiro, D.R., Wang, F., Schleif, W.A., Liang, X., Zhang, Z.-Q., Tobery, T.W., Davies, M.-E., McDermott, A.B., O'Connor, D.H., Fridman, A., Bagchi, A., Tussey, L.G., Bett, A.J., Finnefrock, A.C., Fu, T.-m., Tang, A., Wilson, K.A., Chen, M., Perry, H.C., Heidecker, G.J., Freed, D.C., Carella, A., Punt, K.S., Sykes, K.J., Huang, L., Ausensi, V.I., Bachinsky, M., Sadasivan-Nair, U., Watkins, D.I., Emini, E.A., and Shiver, J.W. 2005. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79:15547-15555.
28. Cohen, J. 2000. AIDS research. Vaccine studies stymied by shortage of animals. Science 287:959-960.
29. Cosma, A., Nagaraj, R., Bühler, S., Hinkula, J., Busch, D.H., Sutter, G., Goebel, F.D., and Erfle, V. 2003. Therapeutic vaccination with MVAHIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22:21-29.
30. Cox, J.H., Ferrari, M.G., Earl, P., Lane, J.R., Jagodzinski, L.L., Polonis, V.R., Kuta, E.G., Boyer, J.D., Ratto-Kim, S., Eller, L.-A., Pham, D.-T., Hart, L., Montefiori, D., Ferrari, G., Parrish, S., Weiner, D.B., Moss, B., Kim, J.H., Birx, D., and VanCott, T.C. 2012. Inclusion of a CRF01 AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. Vaccine 30:1830-1840.
31. Daniel, M.D., Letvin, N.L., King, N.W., Kannagi, M., Sehgal, P.K., Hunt, R.D., Kanki, P.J., Essex, M., and Desrosiers, R.C. 1985. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228:1201-1204.
32. de Sorrentino, A.H., Marinic, K., Motta, P., Sorrentino, A., López, R., and Illiovich, E. 2000. HLA class I alleles associated with susceptibility or resistance to human immunodeficiency virus type 1 infection among a population in Chaco Province, Argentina. J. Infect.Dis. 182:1523-1526.
33. Delaloye, J., Roger, T., Steiner-Tardivel, Q.-G., Le Roy, D.,Knaup Reymond, M.,Akira, S., Petrilli, V., Gomez, C.E., Perdiguero, B., Tschopp, J., Pantaleo, G., Esteban, M., and Calandra, T. 2009. Innate immune sensing of modified vaccinia virus Ankara (MVA) ismediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 5:e1000480.
34. 89.6P challenge in rhesus macaques. J. Virol. 81:3414-3427.
35. Derdeyn, C.A., Decker, J.M., Bibollet-Ruche, F., Mokili, J.L.,Muldoon, M., Denham, S.A., Heil, M.L., Kasolo, F., Musonda, R., Hahn, B.H., Shaw,G.M.,Korber, B.T., Allen, S., and Hunter, E. 2004. Envelope-constrained neutralizationsensitive HIV-1 after heterosexual transmission. Science 303:2019-2022.
36. Dietrich, E.A., Brennan, G., Ferguson, B., Wiseman, R.W., O'Connor, D., and Hu, S.-L. 2011. Variable prevalence and functional diversity of the antiretroviral restriction factor TRIMCyp in Macaca fascicularis. J. Virol. 85:9956-9963.
37. Edghill-Smith, Y., Venzon, D., Karpova, T., McNally, J., Nacsa, J., Tsai, W.-P., Tryniszewska, E., Moniuszko, M., Manischewitz, J., King, L.R., Snodgrass, S.J., Parrish, J., Markham, P., Sowers, M., Martin, D., Lewis, M.G., Berzofsky, J.A., Belyakov, I.M., Moss, B., Tartaglia, J., Bray, M., Hirsh, V., Golding, H., and Franchini, G. 2003. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J. Infect. Dis. 188:1181-1191.
38. Edwards, A.D., Diebold, S.S., Slack, E.M.C., Tomizawa, H., Hemmi, H., Kaisho, T., Akira, S., and Reis e Sousa, C. 2003. Toll-like receptor expression in murine DC subsets: Lack of TLR7 expression by CD8α+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33:827-833.
39. Emini, E.A., Schleif, W.A., Nunberg, J.H., Conley, A.J., Eda, Y., Tokiyoshi, S., Putney, S.D., Matsushita, S., Cobb, K.E., Jett, C.M., Eichberg, J.W., andMurthy, K.K. 1992. Prevention ofHIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730.
40. Esteban, M. 2009. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum. Vaccin. 5:867-871.
41. Falivene, J., DelMédico Zajac, M.P., Pascutti, M.F., Rodríguez, A.M., Maeto, C., Perdiguero, B., Gómez, C.E., Esteban, M., Calamante, G., and Gherardi, M.M. 2012. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One 7:e32220.
42. Feeney, M.E., Tang, Y., Roosevelt, K.A., Leslie, A.J., McIntosh, K., Karthas, N., Walker, B.D., and Goulder, P.J.R. 2004. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLAB27-positive long-term-nonprogressing child. J. Virol. 78:8927-8930.
43. Feinberg,M.B. and Moore, J.P. 2002. AIDS vaccine models: Challenging challenge viruses. Nat. Med. 8:207-210.
44. Fellay, J., Shianna, K.V., Ge, D., Colombo, S., Ledergerber, B., Weale, M., Zhang, K., Gumbs, C., Castagna, A., Cossarizza, A., Cozzi-Lepri, A., De Luca, A., Easterbrook, P., Francioli, P., Mallal, S., Martinez-Picado, J., Miro, J.M., Obel, N., Smith, J.P., Wyniger, J., Descombes, P., Antonarakis, S.E., Letvin, N.L., McMichael, A.J., Haynes, B.F., Telenti, A., and Goldstein, D.B. 2007. A whole-genome association study of major determinants for host control of HIV-1. Science 317:944-947.
45. mac251 replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure. J. Virol. 85:12399-12409.
46. Fernandez, C.S., Stratov, I., De Rose, R., Walsh, K., Dale, C.J., Smith, M.Z., Agy, M.B., Hu, S.-L.,Krebs,K.,Watkins, D.I.,O'Connor D.,H., Davenport, M.P., and Kent, S.J. 2005. Rapid viral escape at an immunodominant simianhuman immunodeficiency virus cytotoxic Tlymphocyte epitope exacts a dramatic fitness cost. J. Virol. 79:5721-5731.
47. Flynn, N.M., Forthal, D.N., Harro, C.D., Judson, F.N.,Mayer, K.H., and Para, M.F. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-665.
48. Franchini, G., Robert-Guroff, M., Tartaglia, J., Aggarwal, A., Abimiku, A., Benson, J., Markham, P., Limbach, K., Hurteau, G., Fullen, J., Aldrich, K., Miller, N., Sadoff, J., Paoletti, E., and Gallo, R. C. 1995. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. AIDS Res. Hum. Retroviruses 11:909-920.
49. Franchini, G., Gurunathan, S., Baglyos, L., Plotkin, S., and Tartaglia, J. 2004. Poxvirus-based vaccine candidates for HIV: Two decades of experience with special emphasis on canarypox vectors. Exp. Rev. Vaccines 3:S75-S88.
50. Frumkin, L.R., Agy, M.B., Coombs, R.W., Panther, L., Morton, W.R., Koehler, J., Florey, M.J., Dragavon, J., Schmidt, A., Katze, M.G., and Corey, L. 1993. Acute infection of Macaca nemestrina by human immunodeficiency virus type 1. Virology 195:422-431.
51. Fultz, P.N., Nara, P., Barre-Sinoussi, F., Chaput, A., Greenberg, M.L., Muchmore, E., Kieny, M.-P., and Girard, M. 1992. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 256:1687-1689.
52. Gallimore, A., Cranage, M., Cook, N., Almond, N., Bootman, J., Rud, E., Silvera, P., Dennis, M., Corcoran, T., Stott, J., McMichael, A., and Gotch, F. 1995. Early suppression of SIV replication by CD8+nef-specific cytotoxic T cells in vaccinated macaques. Nat. Med. 1:1167-1173.
53. Gallo,R.C., Salahuddin, S.Z., Popovic, M., Shearer, G.M., Kaplan, M., Haynes, B.F., Palker, T.J., Redfield, R., Oleske, J., Safai, B.,White, G., Foster, P., and Markham, P.D. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500-503.
54. García-Arriaza, J., Nájera, J.L., Gómez, C.E., Tewabe, N., Sorzano, C.O.S., Calandra, T., Roger, T., and Esteban, M. 2011. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 6: e24244.
55. Gardner, M.B. and Luciw, P.A. 1989. Animal models of AIDS. FASEB J. 3:2593-2606.
56. Genescà, M., Ma, Z.-M., Wang, Y., Assaf, B., Qureshi, H., Fritts, L., Huang, Y., McChesney, M.B., and Miller, C.J. 2012. Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge. J. Virol. 86: 9188-9200.
57. Gibbs, R.A., Rogers, J., Katze, M.G., Bumgarner, R., Weinstock, G.M., Mardis, E.R., Remington, K.A., Strausberg, R.L., Venter, J.C., Wilson, R.K., Batzer, M.A., Bustamante, C.D., Eichler, E.E., Hahn, M.W., Hardison, R.C., Makova, K.D., Miller, W., Milosavljevic, A., Palermo, R.E., Siepel, A., Sikela, J.M., Attaway, T., Bell, S., Bernard, K.E., Buhay, C.J., Chandrabose, M.N., Dao, M., Davis, C., Delehaunty, K.D., Ding, Y., Dinh, H.H., Dugan-Rocha, S., Fulton, L.A., Gabisi, R.A., Garner, T.T., Godfrey, J., Hawes, A.C., Hernandez, J., Hines, S., Holder, M., Hume, J., Jhangiani, S.N., Joshi, V., Khan, Z.M., Kirkness, E.F., Cree, A., Fowler, R.G., Lee, S., Lewis, L.R., Li, Z., Liu, Y.-s., Moore, S.M., Muzny, D., Nazareth, L.V., Ngo, D.N., Okwuonu, G.O., Pai, G., Parker, D., Paul, H.A., Pfannkoch, C., Pohl, C.S., Rogers, Y.-H., Ruiz, S.J., Sabo, A., Santibanez, J., Schneider, B.W., Smith, S.M., Sodergren, E., Svatek, A.F., Utterback, T.R.,Vattathil, S.,Warren,W.,White, C.S., Chinwalla, A.T., Feng, Y., Halpern, A.L., Hillier, L.W., Huang, X.,Minx, P., Nelson, J.O., Pepin, K.H., Qin, X., Sutton, G.G., Venter, E., Walenz, B.P., Wallis, J.W., Worley, K.C., Yang, S.-P., Jones, S.M., Marra, M.A., Rocchi, M., Schein, J.E., Baertsch, R., Clarke, L., Csürös, M., Glasscock, J., Harris, R.A., Havlak, P., Jackson, A.R., Jiang, H., Liu, Y., Messina, D.N., Shen, Y., Song, H.X.-Z., Wylie, T., Zhang, L., Birney, E., Han, K., Konkel,M.K., Lee, J., Smit, A.F.A., Ullmer, B.,Wang, H., Xing, J., Burhans, R., Cheng, Z., Karro, J.E., Ma, J., Raney, B., She, X., Cox, M.J., Demuth, J.P., Dumas, L.J., Han, S.-G., Hopkins, J., Karimpour-Fard, A., Kim,Y.H., Pollack, J.R.,Vinar, T.,Addo-Quaye, C., Degenhardt, J., Denby, A., Hubisz, M.J., Indap, A., Kosiol, C., Lahn, B.T., Lawson, H.A., Marklein, A., Nielsen, R., Vallender, E.J., Clark, A.G., Ferguson, B., Hernandez, R.D., Hirani, K., Kehrer-Sawatzki, H., Kolb, J., Patil, S., Pu, L.-L., Ren, Y., Smith, D.G., Wheeler, D.A., Schenck, I., Ball, E.V., Chen, R., Cooper, D.N., Giardine, B., Hsu, F., Kent, W.J., Lesk, A., Nelson, D.L., O'Brien, W.E., Prüfer, K., Stenson, P.D.,Wallace, J.C.,Ke, H., Liu,X.-M.,Wang, P., Xiang, A.P., Yang, F., Barber, G.P., Haussler, D., Karolchik, D., Kern, A.D., Kuhn, R.M., Smith, K.E., and Zwieg, A.S. 2007. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316:222-234.
58. Girard,M., Kieny, M.-P., Pinter,A., Barre-Sinoussi, F., Nara, P., Kolbe, H., Kusumi, K., Chaput, A., Reinhart, T., Muchmore, E., Ronco, J., Kaczorek, M., Gomard, E., Gluckman, J.-C., and Fultz, P.N. 1991. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. U.S.A. 88:542-546.
59. Girard, M., van der Ryst, E., Barré-Sinoussi, F., Nara, P., Tartaglia, J., Paoletti, E., Blondeau, C., Jennings, M., Verrier, F., Meignier, B., and Fultz, P.N. 1997. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus. Virology 232:98-104.
60. Girard, M., Mahoney, J., Wei, Q., van der Ryst, E.,Muchmore, E., Barré-Sinoussi, F., and Fultz, P.N. 1998. Genital infection of female chimpanzees with human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 14:1357-1367.
61. Goepfert, P.A., Elizaga, M.L., Sato, A., Qin, L., Cardinali, M., Hay, C.M., Hural, J., DeRosa, S.C., DeFawe, O.D., Tomaras, G.D.,Montefiori, D.C.,Xu,Y., Lai, L., Kalams, S.A., Baden, L.R., Frey, S.E., Blattner, W.A., Wyatt, L.S., Moss, B., and Robinson, H.L. 2011. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J. Infect. Dis. 203:610-619.
62. Gómez, C.E., Perdiguero, B., Nájera, J.L., Sorzano, C.O.S., Jiménez, V., González-Sanz, R., and Esteban, M. 2012. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J. Virol. 86:5026-5038.
63. mac251. J. Immunol. 174:2185-2189.
64. Goonetilleke, N., Moore, S., Dally, L., Winstone, N., Cebere, I., Mahmoud, A., Pinheiro, S., Gillespie, G., Brown, D., Loach, V., Roberts, J., Guimaraes-Walker, A., Hayes, P., Loughran, K., Smith, C., De Bont, J., Verlinde, C., Vooijs, D., Schmidt, C., Boaz, M., Gilmour, J., Fast, P., Dorrell, L., Hanke, T., and McMichael, A.J. 2006. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 80:4717-4728.
65. Gorny, M.K., Stamatatos, L., Volsky, B., Revesz, K., Williams, C., Wang, X.-H., Cohen, S., Staudinger, R., and Zolla-Pazner, S. 2005. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79:5232-5237.
66. Gray, R.H., Wawer, M.J., Brookmeyer, R., Sewankambo, N.K., Serwadda, D., Wabwire-Mangen, F., Lutalo, T., Li, X., vanCott, T., and Quinn, T.C. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357:1149-1153.
67. Guerra, S., Nájera, J.L., González, J.M., López-Fernández, L.A., Climent, N., Gatell, J.M., Gallart, T., and Esteban, M. 2007. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J. Virol. 81:8707-8721.
68. Haase, A.T. 2011. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu. Rev. Med. 62:127-139.
69. Hanke, T., Neumann, V.C., Blanchard, T.J., Sweeney, P., Hill, A.V.S., Smith, G.L., and McMichael, A. 1999. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17:589-596.
70. Hansen, S.G., Ford, J.C., Lewis, M.S., Ventura, A.B., Hughes, C.M., Coyne-Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., Legasse, A.W., Chiuchiolo, M.J., Parks, C.L., Axthelm, M.K., Nelson, J.A., Jarvis, M.A., Piatak, M. Jr., Lifson, J.D., and Picker, L.J. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-527.
71. Harari, A., Bart, P.-A., Stöhr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., Burnet, S., Cellerai, C., Erlwein, O., Barber, T., Moog, C., Liljestrom, P., Wagner, R., Wolf, H., Kraehenbuhl, J.-P., Esteban, M., Heeney, J., Frachette, M.-J., Tartaglia, J., McCormack, S., Babiker, A., Weber, J., and Pantaleo, G. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and longlasting T cell responses. J. Exp. Med. 205:63-77.
72. Harenberg, A., Guillaume, F., Ryan, E.J., Burdin, N., and Spada, F. 2008. Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells. Vaccine 26:5004-5013.
73. Harouse, J.M., Gettie, A., Tan, R.C.H., Blanchard, J., and Cheng-Mayer, C. 1999. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284:816-819.
74. Hatziioannou, T., Perez-Caballero, D., Yang, A., Cowan, S., and Bieniasz, P.D. 2004. Retrovirus resistance factors Ref1 and Lv1 are speciesspecific variants of TRIM5a. Proc. Natl. Acad. Sci. U.S.A. 101:10774-10779.
75. Haynes, B.F., Gilbert, P.B., McElrath, M.J., Zolla-Pazner, S., Tomaras, G.D., Alam, S.M., Evans, D.T., Montefiori, D.C., Karnasuta, C., Sutthent, R., Liao, H.-X., DeVico, A.L., Lewis, G.K., Williams, C., Pinter, A., Fong, Y., Janes, H., DeCamp, A., Huang, Y., Rao, M., Billings, E., Karasavvas, N., Robb, M.L., Ngauy, V., de Souza, M.S., Paris, R., Ferrari, G., Bailer, R.T., Soderberg, K.A., Andrews, C., Berman, P.W., Frahm, N., De Rosa, S.C., Alpert, M.D., Yates, N.L., Shen, X.,Koup, R.A., Pitisuttithum, P., Kaewkungwal, J., Nitayaphan, S., Rerks-Ngarm, S., Michael, N.L., and Kim, J.H. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286.
76. Heeney, J.L., Dalgleish, A.G., and Weiss, R.A. 2006. Origins of HIV and the evolution of resistance to AIDS. Science 313:462-466.
77. + T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol. 167:7180-7191.
78. mac251-infected macaques. Virology 304:125-134.
79. + T-cell responses. J. Immunol. 169:4778-4787.
80. Hel, Z., Tsai, W.-P., Tryniszewska, E., Nacsa, J., Markham, P.D., Lewis, M.G., Pavlakis, G.N., Felber, B.K., Tartaglia, J., and Franchini, G. 2006. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J. Immunol. 176:85-96.
81. Helmuth, E.F., Letvin, N.L., and Margolin, D.H. 2000. Germline repertoire of the immunoglobulin V(H)3 family in rhesus monkeys. Immunogenetics 51:519-527.
82. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K.,Wagner, H., Takeda, K., and Akira, S. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745.
83. Henrickson, R.V., Maul, D.H., Osborn, K.G., Sever, J.L., Madden, D.L., Ellingsworth, L.R., Anderson, J.H., Lowenstine, L.J., and Gardner, M.B. 1983. Epidemic of acquired immunodeficiency in rhesus monkeys. Lancet 1:388-390.
84. Hessell, A.J., Rakasz, E.G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D.N., Koff, W.C., Watkins, D.I., and Burton, D.R. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at lowserum neutralizing titers. PLoS Pathog. 5:e1000433.
85. Higashino, A., Sakate, R., Kameoka, Y., Takahashi, I., Hirata, M., Tanuma, R., Masui, T., Yasutomi, Y., and Osada, N. 2012. Whole-genome sequencing and analysis of the Malaysian cynomolgus macaque (Macaca fascicularis) genome. Genome Biol. 13:R58.
86. Himathongkham, S. and Luciw, P.A. 1996. Restriction ofHIV-1 (subtype B) replication at the entry step in rhesus macaque cells. Virology 219:485-488.
87. Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdörfer, B., Giese, T., Endres, S., and Hartmann, G. 2002. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168:4531-4537.
88. Hrecka, K., Hao, C., Gierszewska, M., Swanson, S.K., Kesik-Brodacka, M., Srivastava, S., Florens, L., Washburn, M.P., and Skowronski, J. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474:658-661.
89. Jarrossay, D., Napolitani, G., Colonna, M., Sallusto, F., and Lanzavecchia, A. 2001. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 31:3388-3393.
90. mac infection in Chinese and Indian rhesus macaques: Effects of splenectomy on virus burden. Virology 200:436-446.
91. + T cells and AIDS in pig-tailed macaques. J. Virol. 70:3189-3197.
92. Kadowaki, N., Ho, S., Antonenko, S., de Waal Malefyt, R.W., Kastelein, R.A., Bazan, F., and Liu, Y.-J. 2001. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194:863-869.
93. Kaiser, S.M., Malik, H.S., and Emerman, M. 2007. Restriction of an extinct retrovirus by the human TRIM5a antiviral protein. Science 316:1756-1758.
94. Kaizu, M., Weiler, A.M., Weisgrau, K.L., Vielhuber, K.A., May, G., Piaskowski, S.M., Furlott, J., Maness, N.J., Friedrich, T.C., Loffredo, J.T., Usborne, A., and Rakasz, E.G., 2006. Repeated intravaginal inoculation with cell-associated simian immunodeficiency virus results in persistent infection of nonhuman primates. J. Infect. Dis. 194:912-916.
95. Keckesova, Z., Ylinen, L.M.J., and Towers, G.J. 2004. The human and African green monkey TRIM5a genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. U.S.A. 101:10780-10785.
96. Keele, B.F. and Estes, J.D. 2011. Barriers to mucosal transmission of immunodeficiency viruses. Blood 118:839-846.
97. Keele, B.F., Van Heuverswyn, F., Li, Y., Bailes, E., Takehisa, J., Santiago, M.L., Bibollet-Ruche, F., Chen, Y., Wain, L.V., Liegeois, F., Loul, S., Ngole, E.M., Bienvenue, Y., Delaporte, E., Brookfield, J.F.Y., Sharp, P.M., Shaw, G.M., Peeters, M., and Hahn, B.H. 2006. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313:523-526.
98. Keele, B.F., Giorgi, E.E., Salazar-Gonzalez, J.F., Decker, J.M., Pham, K.T., Salazar, M.G., Sun, C., Grayson, T.,Wang, S., Li, H.,Wei, X., Jiang, C., Kirchherr, J.L., Gao, F., Anderson, J.A., Ping, L.-H., Swanstrom, R., Tomaras, G.D., Blattner, W.A., Goepfert, P.A., Kilby, J.M., Saag, M.S., Delwart, E.L., Busch, M.P., Cohen, M.S., Montefiori, D.C., Haynes, B.F., Gaschen, B.,Athreya,G.S., Lee, H.Y.,Wood, N., Seoighe, C., Perelson, A.S., Bhattacharya, T., Korber, B.T., Hahn, B.H., and Shaw, G.M. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 105:7552-7557.
99. mac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206:1117-1134.
100. Ketloy, C., Engering, A., Srichairatanakul,U., Limsalakpetch, A., Yongvanitchit, K., Pichyangkul, S., and Ruxrungtham, K. 2008. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from nonhuman primates. Vet. Immunol. Immunopathol. 125:18-30.
101. Kibler, K.V., Gomez, C.E., Perdiguero, B., Wong, S., Huynh, T., Holechek, S., Arndt,W., Jimenez, V., Gonzalez-Sanz, R., Denzler, K., Haddad, E.K.,Wagner, R., Sékaly, R.P., Tartaglia, J., Pantaleo, G., Jacobs, B.L., and Esteban, M. 2011. Improved NYVAC-based vaccine vectors. PLoS One 6:e25674.
102. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53.
103. Kirmaier, A., Wu, F., Newman, R.M., Hall, L.R., Morgan, J.S., O'Connor, S., Marx, P.A., Meythaler, M., Goldstein, S., Buckler-White, A., Kaur, A., Hirsch, V.M., and Johnson, W.E. 2010. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol. 8:e1000462.
104. Kootstra, N.A.,Münk, C., Tonnu, N., Landau, N.R., and Verma, I.M. 2003. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc. Natl. Acad. Sci. U.S.A. 100:1298-1303.
105. Krebs, K.C., Jin, Z., Rudersdorf, R., Hughes, A.L., and O'Connor, D.H. 2005. Unusually high frequency MHC class I alleles in Mauritian origin cynomolgus macaques. J. Immunol. 175:5230-5239.
106. Krug, A., Towarowski, A., Britsch, S., Rothenfusser, S., Hornung, V., Bals, R., Giese, T., Engelmann, H., Endres, S., Krieg, A.M., and Hartmann, G. 2001. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31:3026-3037.
107. Laguette, N., Sobhian, B., Casartelli, N., Ringeard, M., Chable-Bessia, C., Ségéral, E., Yatim, A., Emiliani, S., Schwartz, O., and Benkirane, M. 2011. SAMHD1 is the dendriticand myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474:654-657.
108. Lai, L., Voödrös, D., Kozlowski, P.A., Montefiori, D.C., Wilson, R.L., Akerstrom, V.L., Chennareddi, L., Yu, T., Kannanganat, S., Ofielu, L., Villinger, F., Wyatt, L.S., Moss, B., Amara, R.R., and Robinson, H.L. 2007. GMCSF DNA: An adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369:153-167.
109. Lai, L., Kwa, S., Kozlowski, P.A.,Montefiori, D.C., Ferrari, G., Johnson,W.E., Hirsch, V., Villinger, F., Chennareddi, L., Earl, P.L., Moss, B., Amara, R.R., and Robinson, H.L. 2011. Prevention of infection by a granulocyte-macrophage colonystimulating factor co-expressing DNA/modified vacciniaAnkara simian immunodeficiency virus vaccine. J. Infect. Dis. 204:164-173.
110. mac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 30:1737-1745.
111. Lakhashe, S.K., Velu, V., Sciaranghella, G., Siddappa, N.B., DiPasquale, J.M., Hemashettar, G., Yoon, J.K., Rasmussen, R.A., Yang, F., Lee, S.J.,Montefiori, D.C.,Novembre, F.J.,Villinger, F., Amara, R.R., Kahn, M., Hu, S.-L., Li, S., Li, Z., Frankel, F.R., Robert-Guroff, M., Johnson, W.E., Lieberman, J., and Ruprecht, R.M. 2011. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: Efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 29:5611-5622.
112. Leslie, A.J., Pfafferott, K.J., Chetty, P., Draenert, R., Addo, M.M., Feeney, M., Tang, Y., Holmes, E.C.,Allen, T., Prado, J.G.,Altfeld, M.,Brander, C., Dixon, C., Ramduth, D., Jeena, P., Thomas, S.A., St John, A.,Roach,T.A.,Kupfer,B., Luzzi, G., Edwards, A., Taylor, G., Lyall, H., Tudor-Williams, G., Novelli, V., Martinez-Picado, J., Kiepiela, P., Walker, B.D., and Goulder, P.J.R. 2004. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10:282-289.
113. Letvin, N.L., Eaton, K.A., Aldrich, W.R., Sehgal, P.K., Blake, B.J., Schlossman, S.F., King, N.W., and Hunt, R.D. 1983. Acquired immunodeficiency syndrome in a colony of macaque monkeys. Proc. Natl. Acad. Sci. U.S.A. 80:2718-2722.
114. Letvin, N.L., Daniel, M.D., Sehgal, P.K., Desrosiers, R.C., Hunt, R.D., Waldron, L.M., MacKey, J.J., Schmidt, D.K., Chalifoux, L.V., and King, N.W. 1985. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 230:71-73.
115. Letvin, N.L., Rao, S.S., Montefiori, D.C., Seaman, M.S., Sun,Y., Lim, S.-Y.,Yeh,W.W., Asmal, M., Gelman, R.S., Shen, L.,Whitney, J.B., Seoighe, C., Lacerda, M., Keating, S., Norris, P.J., Hudgens, M.G., Gilbert, P.B., Buzby, A.P., Mach, L.V., Zhang, J., Balachandran, H., Shaw, G.M., Schmidt, S.D., Todd, J.-P., Dodson, A., Mascola, J.R., and Nabel, G.J. 2011. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 3:81ra36.
116. mac251 replication in Indian-origin rhesus monkeys. PLoS Genet. 6:e1000997.
117. Lim, S.-Y., Rogers, T., Chan, T., Whitney, J.B., Kim, J., Sodroski, J., and Letvin, N.L. 2010b. TRIM5a modulates immunodeficiency virus control in rhesus monkeys. PLoS Pathog. 6:e1000738.
118. Ling, B., Veazey, R.S., Luckay, A., Penedo, C., Xu, K., Lifson, J.D., and Marx, P.A. 2002. SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin comparedwith primaryHIV infections in humans. AIDS 16:1489-1496.
119. Link, J.M., Larson, J.E., and Schroeder, H.W. 2005. Despite extensive similarity in germline DH and JH sequence, the adult Rhesus macaque CDR-H3 repertoire differs from human. Mol. Immunol. 42:943-955.
120. Liu, J., Keele, B.F., Li, H., Keating, S., Norris, P.J., Carville, A., Mansfield, K.G., Tomaras, G.D., Haynes, B.F., Kolodkin-Gal, D., Letvin, N.L., Hahn, B.H., Shaw, G.M., and Barouch, D.H. 2010. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J. Virol. 84:10406-10412.
121. Loffredo, J.T., Maxwell, J., Qi, Y., Glidden, C.E., Borchardt, G.J., Soma, T., Bean, A.T., Beal, D.R., Wilson, N.A., Rehrauer, W.M., Lifson, J.D., Carrington, M., and Watkins, D.I. 2007a. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J. Virol. 81:8827-8832.
122. + T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation. PLoS One 2:e1152.
123. mac239 replication. J. Virol. 82:1723-1738.
124. Loffredo, J.T., Sidney, J., Bean, A.T., Beal, D.R., Bardet, W., Wahl, A., Hawkins, O.E., Piaskowski, S.,Wilson, N.A.,Hildebrand,W.H., Watkins, D.I., and Sette, A. 2009. Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. J. Immunol. 182: 7763-7775.
125. London, W.T., Sever, J.L., Madden, D.L., Henrickson, R.V., Gravell, M., Maul, D.H., Dalakas, M.C., Osborn, K.G., Houff, S.A., and Gardner, M.B. 1983. Experimental transmission of simian acquired immunodeficiency syndrome (SAIDS) and Kaposi-like skin lesions. Lancet 2: 869-873.
126. 287 challenge. Virology 242:150-160.
127. mac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in rampup phase plasma. AIDS Res. Hum. Retroviruses 27:1259-1269.
128. + T lymphocytes against an immunodominant cryptic epitope select for viral escape. J. Exp. Med. 204:2505-2512.
129. + T cell memory.AIDS Res. Hum. Retroviruses 24:505-519.
130. Manrique, M., Kozlowski, P.A., Wang, S.-W., Wilson, R.L., Micewicz, E., Montefiori, D.C., Mansfield, K.G., Carville, A., and Aldovini, A. 2009. Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol. 2:536-550.
131. + T cell deficits in cytokine secretion profile are dependent on monkey origin. Viral Immunol. 19:679-689.
132. mac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: Transmission efficiency, viral loads, and antibody responses. AIDS Res. Hum. Retroviruses 17:1455-1466.
133. Marx, P.A., Spira, A.I., Gettie, A., Dailey, P.J., Veazey, R.S., Lackner, A.A., Mahoney, C.J., Miller, C.J., Claypool, L.E., Ho, D.D., and Alexander, N.J. 1996. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2:1084-1089.
134. + cell depletion in Macaca nemestrina. J. Med. Primatol. 29:114-126.
135. McCormack, S., Stöhr, W., Barber, T., Bart, P.-A., Harari, A.,Moog, C., Ciuffreda, D., Cellerai, C., Cowen, M., Gamboni, R., Burnet, S., Legg, K., Brodnicki, E.,Wolf, H.,Wagner, R., Heeney, J., Frachette, M.-J., Tartaglia, J., Babiker, A., Pantaleo, G., and Weber, J. 2008. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 26:3162-3174.
136. mac239 viremia in adenovirusboosted and DNA-primed Mamu-A*01-positive rhesus macaques. J. Virol. 79:15556-15566.
137. McLellan, J.S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O'Dell, S., Patel, N., Shahzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J.C., Chuang, G.-Y., Diwanji, D., Georgiev, I., Kwon, Y.D., Lee, D., Louder, M.K., Moquin, S., Schmidt, S.D., Yang, Z.-Y., Bonsignori, M., Crump, J.A., Kapiga, S.H., Sam, N.E., Haynes, B.F., Burton, D.R., Koff,W.C.,Walker, L.M., Phogat, S.,Wyatt, R., Orwenyo, J.,Wang, L.-X., Arthos, J., Bewley, C.A., Mascola, J.R., Nabel, G.J., Schief, W.R., Ward, A.B., Wilson, I.A., and Kwong, P.D. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343.
138. Meek, K., Eversole, T., and Capra, J.D. 1991. Conservation of the most JH proximal Ig VH gene segment (VHVI) throughout primate evolution. J. Immunol. 146:2434-2438.
139. Mogensen, T.H., Melchjorsen, J., Larsen, C.S., and Paludan, S.R. 2010. Innate immune recognition and activation during HIV infection. Retrovirology 7:54.
140. Moss, B. 1991. Vaccinia virus: A tool for research and vaccine development. Science 252:1662.
141. mac239 replication. J. Virol. 77:2736-2740.
142. Mühl, T., Krawczak, M., ten Haaft, P., Hunsmann, G., and Sauermann, U. 2002.MHCclass I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys. J. Immunol. 169:3438-3446.
143. Münk, C., Brandt, S.M., Lucero, G., and Landau, N.R. 2002. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc. Natl. Acad. Sci. U.S.A. 99:13843-13848.
144. Murphey-Corb, M., Martin, L.N., Rangan, S.R.S., Baskin, G.B., Gormus, B.J., Wolf, R.H., Andes, W.A.,West, M., and Montelaro, R.C. 1986. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 321:435-437.
145. Myagkikh, M., Alipanah, S., Markham, P.D., Tartaglia, J., Paoletti, E., Gallo, R.C., Franchini, G., and Robert-Guroff, M. 1996. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retroviruses 12:985-992.
146. mac251-infected macaques. Vaccine 22:597-606.
147. Nakayama, E.E. and Shioda, T. 2012. TRIM5a and species tropism of HIV/SIV. Front. Microbiol. 3:13.
148. + T cells as key targets in mucosal transmission. PLoS Pathog. 7:e1001301.
149. Neil, S.J., Zang, T., and Bieniasz, P.D. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430.
150. Newman, R.M., Hall, L., Connole, M., Chen, G.-L., Sato, S., Yuste, E., Diehl, W., Hunter, E., Kaur, A., Miller, G.M., and Johnson, W.E. 2006. Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5a. Proc. Natl. Acad. Sci. U.S.A. 103:19134-19139.
151. AD8 by serial passaging in rhesus macaques. J. Virol. 84:4769-4781.
152. Nisole, S., Lynch, C., Stoye, J.P., and Yap, M.W. 2004. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. U.S.A. 101:13324-13328.
153. O'Brien, S.J. andMoore, J.P. 2000. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 177:99-111.
154. O'Connor, D.H., Allen, T.M., Vogel, T.U., Jing, P., DeSouza, I.P., Dodds, E., Dunphy, E.J., Melsaether, C., Mothé, B., Yamamoto, H., Horton, H.,Wilson, N., Hughes, A.L., andWatkins, D.I. 2002. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8:493-499.
155. O'Connor, D.H., Mothé, B.R., Weinfurter, J.T., Fuenger, S., Rehrauer, W.M., Jing, P., Rudersdorf, R.R., Liebl, M.E., Krebs, K., Vasquez, J., Dodds, E., Loffredo, J., Martin, S., McDermott, A.B., Allen, T.M., Wang, C., Doxiadis, G.G., Montefiori, D.C., Hughes, A., Burton, D.R., Allison, D.B., Wolinsky, S.M., Bontrop, R., Picker, L.J., and Watkins, D.I. 2003. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J. Virol. 77:9029-9040.
156. Otting, N., Heijmans, C.M., Noort, R.C., de Groot, N.G., Doxiadis, G.G.M., van Rood, J.J., Watkins, D.I., and Bontrop, R.E. 2005. Unparalleled complexity of the MHC class I region in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 102:1626-1631.
157. Padian, N.S., Shiboski, S.C., Glass, S.O., and Vittinghoff, E. 1997. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: Results from a ten-year study. Am. J. Epidemiol. 146:350-357.
158. mac-induced immunodeficiency. J. Virol. 76:292-302.
159. KU2 RNA levels. J. Virol. 80:3732-3742.
160. Pantaleo, G., Esteban, M., Jacobs, B., and Tartaglia, J. 2010. Poxvirus vector-based HIV vaccines. Curr. Opin. HIV AIDS 5:391-396.
161. Pegu, P., Vaccari, M., Gordon, S., Keele, B.F., Doster, M., Guan, Y., Ferrari, G., Pal, R., Ferrari, M.G., Whitney, S., Hudacik, L., Billings, E., Rao, M., Montefiori, D., Tomaras, G., Alam, S.M., Fenizia, C., Lifson, J.D., Stablein, D., Tartaglia, J., Michael,N., Kim, J.,Venzon, D., and Franchini, G. 2013. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 87:1708-1719.
162. Pereyra, F., Jia, X., McLaren, P.J., Telenti, A., de Bakker, P.I.W., Walker, B.D., and International HIV Controllers Study. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-1557.
163. Perreau, M., Welles, H.C., Harari, A., Hall, O., Martin, R., Maillard, M., Dorta, G., Bart, P.-A., Kremer, E.J., Tartaglia, J., Wagner, R., Esteban, M., Levy, Y., and Pantaleo, G. 2011. DNA/NYVAC vaccine regimen induces HIVspecific CD4 and CD8 T-cell responses in intestinal mucosa. J. Virol. 85:9854-9862.
164. Perron, M.J., Stremlau, M., Song, B., Ulm, W., Mulligan, R.C., and Sodroski, J. 2004. TRIM5a mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. U.S.A. 101:11827-11832.
165. Pilcher, C.D., Joaki, G., Hoffman, I.F., Martinson, F.E., Mapanje, C., Stewart, P.W., Powers, K.A., Galvin, S., Chilongozi, D., Gama, S., Price, M.A., Fiscus, S.A., and Cohen, M.S. 2007. Amplified transmission of HIV-1: Comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 21:1723-1730.
166. Pitisuttithum, P.,Gilbert, P., Gurwith,M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J.W., and Choopanya, K. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671.
167. Price, A.J., Marzetta, F., Lammers, M., Ylinen, L.M.J., Schaller, T., Wilson, S.J., Towers, G.J., and James, L.C. 2009. Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat. Struct. Mol. Biol. 16:1036-1042.
168. + T cell responses in SIV infection. J. Exp. Med. 206: 923-936.
169. Quakkelaar, E.D., Redeker, A., Haddad, E.K., Harari, A.,McCaughey, S.M., Duhen, T., Filali-Mouhim, A., Goulet, J.-P., Loof, N.M., Ossendorp, F., Perdiguero, B., Heinen, P., Gomez, C.E., Kibler, K.V., Koelle, D.M., Sékaly, R.P., Sallusto, F., Lanzavecchia, A., Pantaleo, G., Esteban, M., Tartaglia, J., Jacobs, B.L., and Melief, C.J.M. 2011. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One 6:e16819.
170. mac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replicationdefective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J. Virol. 86:2239-2250.
171. Ranasinghe, S., Flanders, M., Cutler, S., Soghoian, D.Z., Ghebremichael, M., Davis, I., Lindqvist, M., Pereyra, F., Walker, B.D., Heckerman, D., and Streeck, H. 2012. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J. Virol. 86:277-283.
172. Reimann, K.A., Li, J.T., Veazey, R., Halloran, M., Park, I.-W., Karlsson, G.B., Sodroski, J., and Letvin, N.L. 1996. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:6922-6928.
173. mac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J. Virol. 79:8878-8885.
174. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., Benenson, M., Gurunathan, S., Tartaglia, J., McNeil, J.G., Francis, D.P., Stablein, D., Birx, D.L., Chunsuttiwat, S., Khamboonruang, C., Thongcharoen, P., Robb, M.L., Michael, N.L., Kunasol, P., and Kim, J.H. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
175. Rerks-Ngarm, S., Paris, R.M., Chunsutthiwat, S., Premsri, N., Namwat, C., Bowonwatanuwong, C., Li, S.S., Kaewkungkal, J., Trichavaroj, R., Churikanont, N., de Souza, M.S., Andrews, C., Francis, D., Adams, E., Flores, J., Gurunathan, S., Tartaglia, J., O'Connell, R.J., Eamsila, C., Nitayaphan, S., Ngauy, V., Thongcharoen, P., Kunasol, P.,Michael, N.L., Robb, M.L., Gilbert, P.B., and Kim, J.H. 2013. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquiredHIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAXB/E. J. Infect. Dis. 207:1195-1205.
176. + T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: Too late and too little. J. Virol. 79:9228-9235.
177. Reynolds, M.R., Weiler, A.M., Piaskowski, S.M., Piatak, M. Jr., Robertson, H.T., Allison, D.B., Bett, A.J., Casimiro, D.R., Shiver, J.W.,Wilson, N.A., Lifson, J.D.,Koff,W.C., andWatkins, D.I. 2012. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 30:4465-4475.
178. Rothaeusler, K., Ma, Z.-M., Qureshi, H., Carroll, T.D., Rourke, T., McChesney, M.B., and Miller, C.J. 2012. Antiviral antibodies and T cells are present in the foreskin of simian immunodeficiency virus-infected rhesus macaques. J. Virol. 86:7098-7106.
179. Rowland-Jones, S., Pinheiro, S., and Kaul, R. 2001. New insights into host factors in HIV-1 pathogenesis. Cell 104:473-476.
180. Royce, R.A., Seña, A., Cates, W. Jr., and Cohen, M.S. 1997. Sexual transmission of HIV. N. Engl. J. Med. 336:1072-1078.
181. Saito, A., Kono, K., Nomaguchi, M., Yasutomi, Y., Adachi, A., Shioda, T., Akari, H., and Nakayama, E.E. 2012. Geographical, genetic and functional diversity of antiretroviral host factor TRIMCyp in cynomolgus macaque (Macaca fascicularis). J. Gen. Virol. 93:594-602.
182. Salazar-Gonzalez, J.F., Bailes, E., Pham, K.T., Salazar, M.G., Guffey, M.B., Keele, B.F., Derdeyn, C.A., Farmer, P., Hunter, E., Allen, S., Manigart, O., Mulenga, J., Anderson, J.A., Swanstrom, R., Haynes, B.F., Athreya, G.S., Korber, B.T.M., Sharp, P.M., Shaw, G.M., and Hahn, B.H. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82:3952-3970.
183. Sallé, B., Brochard, P., Bourry, O., Mannioui, A., Andrieu, T., Prevot, S., Dejucq-Rainsford, N., Dereuddre-Bosquet, N., and Le Grand, R. 2010. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J. Infect. Dis. 202:337-344.
184. Sandström, E., Nilsson, C., Hejdeman, B., Bråve, A., Bratt, G., Robb, M., Cox, J., VanCott, T., Marovich, M., Stout, R., Aboud, S., Bakari, M., Pallangyo, K., Ljungberg, K., Moss, B., Earl, P., Michael, N., Birx, D., Mhalu, F., Wahren, B., and Biberfeld, G. 2008. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198:1482-1490.
185. Santiago, M.L., Range, F., Keele, B.F., Li, Y., Bailes, E., Bibollet-Ruche, F., Fruteau, C., Noë, R., Peeters, M., Brookfield, J.F.Y., Shaw, G.M., Sharp, P.M., and Hahn, B.H. 2005. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d'Ivoire: Implications for the origin of epidemic human immunodeficiency virus type 2. J. Virol. 79:12515-12527.
186. Sawyer, S.L., Wu, L.I., Emerman, M., and Malik, H.S. 2005. Positive selection of primate TRIM5a identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. U.S.A. 102:2832-2837.
187. Sayah, D.M., Sokolskaja, E., Berthoux, L., and Luban, J. 2004. CyclophilinAretrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430:569-573.
188. Scinicariello, F., Engleman, C.N., Jayashankar, L., McClure, H.M., and Attanasio, R. 2004. Rhesus macaque antibody molecules: Sequences and heterogeneity of alpha and gamma constant regions. Immunology 111:66-74.
189. Sharp, P.M., Shaw, G.M., and Hahn, B.H. 2005. Simian immunodeficiency virus infection of chimpanzees. J. Virol. 79:3891-3902.
190. Shedlock, D.J., Silvestri, G., and Weiner, D.B. 2009. Monkeying around with HIV vaccines: Using rhesus macaques to define "gatekeepers" for clinical trials. Nat. Rev. Immunol. 9: 717-728.
191. Shibata, R., Sakai, H., Kawamura, M., Tokunaga, K., and Adachi, A. 1995. Early replication block of human immunodeficiency virus type 1 in monkey cells. J. Gen. Virol. 76:2723-2730.
192. Shiver, J.W., Fu, T.-M., Chen, L., Casimiro, D.R., Davies, M.-E., Evans, R.K., Zhang, Z.-Q., Simon, A.J., Trigona, W.L., Dubey, S.A., Huang, L., Harris, V.A., Long, R.S., Liang, X., Handt, L., Schleif, W.A., Zhu, L., Freed, D.C., Persaud, N.V., Guan, L., Punt, K.S., Tang, A., Chen, M., Wilson, K.A., Collins, K.B., Heidecker, G.J., Fernandez, V.R., Perry, H.C., Joyce, J.G., Grimm, K.M., Cook, J.C., Keller, P.M., Kresock, D.S., Mach, H., Troutman, R.D., Isopi, L.A., Williams, D.M., Xu, Z., Bohannon, K.E., Volkin, D.B., Montefiori, D.C., Miura, A., Krivulka, G.R., Lifton, M.A., Kuroda,M.J., Schmitz, J.E., Letvin, N.L., Caulfield, M.J., Bett, A.J., Youil, R., Kaslow, D.C., and Emini, E.A. 2002. Replicationincompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
193. Sina, S.T., Ren, W., and Cheng-Mayer, C. 2011. Coreceptor use in nonhuman primate models of HIV infection. J. Transl. Med. 9:S7.
194. Smith, M.Z., Dale, C.J., De Rose, R., Stratov, I., Fernandez, C.S., Brooks, A.G., Weinfurter, J., Krebs, K., Riek, C., Watkins, D.I., O'Connor D.H., and Kent, S.J. 2005a. Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes. J. Virol. 79:684-695.
195. Smith, M.Z., Fernandez, C.S., Chung, A., Dale, C.J., De Rose, R., Lin, J., Brooks, A.G., Krebs, K.C., Watkins, D.I., O'Connor, D.H., Davenport, M.P., and Kent, S.J. 2005b. The pigtail macaque MHC class I allele Mane-A*10 presents an immundominant SIV Gag epitope: Identification, tetramer development and implications of immune escape and reversion. J.Med. Primatol. 34:282-293.
196. Sobieszczyk, M.E., Lingappa, J.R., and McElrath, M.J. 2011. Host genetic polymorphisms associated with innate immune factors and HIV-1. Curr. Opin. HIV AIDS 6:427-434.
197. Sodora, D.L., Gettie, A., Miller, C.J., and Marx, P.A. 1998. Vaginal transmission of SIV: Assessing infectivity and hormonal influences in macaques inoculated with cell-free and cellassociated viral stocks. AIDS Res. Hum. Retroviruses 14:S119-S123.
198. Song, B., Gold, B., O'hUigin, C., Javanbakht, H., Li, X., Stremlau,M.,Winkler, C., Dean,M., and Sodroski, J. 2005. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5α exhibits lineage-specific length and sequence variation in primates. J. Virol. 79:6111-6121.
199. Staprans, S.I., Barry, A.P., Silvestri, G., Safrit, J.T., Kozyr, N., Sumpter, B., Nguyen, H., McClure, H., Montefiori, D., Cohen, J.I., and Feinberg, M.B. 2004. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc. Natl. Acad. Sci. U.S.A. 101:13026-13031.
200. + T-cell responses in mucosal tissues of macaques. J. Virol. 76:11659-11676.
201. Stittelaar, K.J., Kuiken, T., de Swart, R.L., van Amerongen, G., Vos, H.W., Niesters, H.G.M., van Schalkwijk, P., van der Kwast, T., Wyatt, L.S.,Moss, B., and Osterhaus, A.D.M.E. 2001. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700-3709.
202. mac251. J. Virol. 84:7083-7095.
203. Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., and Sodroski, J. 2004. The cytoplasmic body component TRIM5α restricts HIV-1 infection in OldWorld monkeys. Nature 427:848-853.
204. Stremlau, M., Perron, M., Welikala, S., and Sodroski, J. 2005. Species-specific variation in the B30.2(SPRY) domain of TRIM5α determines the potency of human immunodeficiency virus restriction. J. Virol. 79:3139-3145.
205. Stromberg, K., Benveniste, R.E., Arthur, L.O., Rabin, H., Giddens, W.E. Jr., Ochs, H.D., Morton, W.R., and Tsai, C.C. 1984. Characterization of exogenous type D retrovirus from a fibroma of a macaque with simian AIDS and fibromatosis. Science 224:289-292.
206. Sui, Y., Zhu, Q., Gagnon, S., Dzutsev, A., Terabe, M., Vaccari, M., Venzon, D., Klinman, D., Strober, W., Kelsall, B., Franchini, G., Belyakov, I.M., and Berzofsky, J.A. 2010. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc. Natl. Acad. Sci. U.S.A. 107:9843-9848.
207. mac251-challenged rhesus macaques. Vaccine 30:59-68.
208. Sun, Y., Santra, S., Schmitz, J.E., Roederer, M., and Letvin, N.L. 2008. Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys. J. Virol. 82:8812-8819.
209. Tan, X., Pearce-Pratt, R., and Phillips, D.M. 1993. Productive infection of a cervical epithelial cell line with human immunodeficiency virus: Implications for sexual transmission. J. Virol. 67:6447-6452.
210. Tartaglia, J., Perkus, M.E., Taylor, J., Norton, E.K., Audonnet, J.-C., Cox,W.I., Davis, S.W., Van der Hoeven, J., Meignier, B., Riviere, M., Languet, B., and Paoletti, E. 1992. NYVAC: A highly attenuated strain of vaccinia virus. Virology 188:217-232.
211. Taylor, J., Meignier, B., Tartaglia, J., Languet, B., Van der Hoeven, J., Franchini, G., Trimarchi, C., and Paoletti, E. 1995. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13:539-549.
212. Trichel, A.M., Rajakumar, P.A., and Murphey-Corb,M. 2002. Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque. J. Med. Primatol. 31:171-178.
213. Urvater, J.A.,McAdam, S.N., Loehrke, J.H., Allen, T.M., Moran, J.L., Rowell, T.J., Rojo, S., López de Castro, J.A., Taurog, J.D., and Watkins, D.I. 2000. A high incidence of Shigella-induced arthritis in a primate species: Major histocompatibility complex class I molecules associated with resistance and susceptibility, and their relationship to HLA-B27. Immunogenetics 51:314-325.
214. + central memoryTcells in protection from simian AIDS. J. Immunol. 175:3502-3507.
215. + T-cell deficiency. J. Virol. 82:9629-9638.
216. mac251 at challenge exposure. J. Virol. 87:3538-3548.
217. mac239 replication in Mamu-B*08-positive macaques. J. Virol. 83:11514-11527.
218. Van Damme, N., Goff, D., Katsura, C., Jorgenson, R.L., Mitchell, R., Johnson, M.C., Stephens, E.B., and Guatelli, J. 2008. The interferoninduced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252.
219. Van Rompay, K.K., Abel, K., Lawson, J.R., Singh, R.P., Schmidt, K.A., Evans, T., Earl, P., Harvey, D., Franchini, G., Tartaglia, J., Montefiori, D., Hattangadi, S., Moss, B., and Marthas, M.L. 2005. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J. Acquir. Immune Defic. Syndr. 38:124-134.
220. VandeWoude, S. and Apetrei, C. 2006. Going wild: Lessons from naturally occurring Tlymphotropic lentiviruses. Clin. Microbiol. Rev. 19:728-762.
221. Verthelyi, D., Kenney, R.T., Seder, R.A., Gam, A.A., Friedag, B., and Klinman, D.M. 2002. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 168:1659-1663.
222. Virgen, C.A., Kratovac, Z., Bieniasz, P.D., and Hatziioannou, T. 2008. Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc. Natl. Acad. Sci. U.S.A. 105:3563-3568.
223. Walker, L.M., Phogat, S.K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J.L., Wrin, T., Simek, M.D., Fling, S., Mitcham, J.L., Lehrman, J.K., Priddy, F.H., Olsen, O.A., Frey, S.M., Hammond, P.W., Kaminsky, S., Zamb, T., Moyle, M., Koff, W.C., Poignard, P., and Burton, D.R. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
224. + memory T cells. Vaccine 27:870-881.
225. Wang, Y. and Lehner, T. 2011. Induction of innate immunity in control of mucosal transmission of HIV. Curr. Opin. HIV AIDS 6:398-404.
226. mac239. J. Virol. 82:4154-4158.
227. + T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. U.S.A. 102:15190-15194.
228. mac239. J. Virol. 80:5875-5885.
229. Wilson, S.J.,Webb, B.L.J.,Maplanka, C., Newman, R.M., Verschoor, E.J., Heeney, J.L., and Towers, G.J. 2008a. Rhesus macaque TRIM5αlleles have divergent antiretroviral specificities. J. Virol. 82:7243-7247.
230. Wilson, S.J., Webb, B.L.J., Ylinen, L.M.J., Verschoor, E., Heeney, J.L., and Towers, G.J. 2008b. Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 105:3557-3562.
231. Wu, Y., Gao, F., Liu, J., Qi, J., Gostick, E., Price, D.A., and Gao, G.F. 2011. Structural basis of diverse peptide accommodation by the rhesus macaque MHC class I molecule Mamu-BWu, Y., Gao, F.17: Insights into immune protection from simian immunodeficiency virus. J. Immunol. 187:6382-6392.
232. 89.6P challenge in rhesus macaques. J. Virol. 14:7161-7173.
233. mac251 challenge. J. Virol. 86:4644-4657.
234. mac239 replication. J. Virol. 80:5074-5077.
235. Yap, M.W., Nisole, S., Lynch, C., and Stoye, J.P. 2004. TRIM5α protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. U.S.A. 101:10786-10791.
236. Yeh,W.W., Rao, S.S., Lim, S.-Y., Zhang, J., Hraber, P.T., Brassard, L.M., Luedemann, C., Todd, J.P., Dodson, A., Shen, L., Buzby, A.P., Whitney, J.B., Korber, B.T., Nabel, G.J., Mascola, J.R., and Letvin, N.L. 2011. The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys. J. Virol. 85:10389-10398.
237. Yu, Q., Jones, B., Hu, N., Chang, H., Ahmad, S., Liu, J., Parrington, M., and Ostrowski, M. 2006. Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage. Vaccine 24:6376-6391.
238. Zhang, Z.-Q., Fu, T.-M., Casimiro, D.R., Davies, M.-E., Liang, X., Schleif, W.A., Handt, L., Tussey, L., Chen, M., Tang, A., Wilson, K.A., Trigona, W.L., Freed, D.C., Tan, C.Y., Horton, M., Emini, E.A., and Shiver, J.W. 2002. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J. Virol. 76: 12845-12854.
239. Zhao, J., Lai, L., Amara, R.R., Montefiori, D.C., Villinger, F., Chennareddi, L., Wyatt, L.S., Moss, B., and Robinson, H.L. 2009. Preclinical studies of human immunodeficiency virus/AIDS vaccines: Inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J. Virol. 83:4102-4111.